Research has shown that achieving maximum natural growth hormone (ГХ) release bythe anterior pituitary can be accomplished, в общем, by combining a growth hormonereleasing hormone (GHRH) analogue with a growth hormone secretagogue receptor(GHSR) agonist. There are multiple combinations that can accomplish this goal, including combining modified GRF with ipamorelin. Конечно, sometimes the goal might be to achieve more specific effects in addition to maximum GH release. другими словами, by finetuning the types of GHRH agonist and GHSR agonist used, it could be possible to createmore targeted outcomes.
In the case of Modified GRF, a potent GHRH analogue, the effects go beyond simply boosting GH release. The peptide has been shown, in animal studies, to have benefits inintestinal inflammation, heart function, and wound healing1, [2], [3]
By adding ipamorelin to the mix with modified GRF, GH release is pulsed to its maximumlevel. lpamorelin, known for its specificity in boosting GH with few additional effects, hasrecently been linked to bone regrowth and matrix stabilization. These effects appear to bein addition to the bone benefits of enhanced GH release[4], [5].
Окончательно, it is possible to boost targeted fat burning, something that both modified GRF andipamorelin cause to a limited degree, with the aid of fragment 176-191. While technicallya GHRH agonist, фрагмент 176-191 has been shown in animal models to be a primaryand potent stimulator of adipocyte catabolism (сжигание жира). The peptide is orders ofmagnitude more potent than most GHRH agonists in stimulating fat metabolism and thusis sometimes referred to as the “lipolytic fragment.” Adding fragment 176-191 to the mix isa way to boost fat burning, particularly in the setting of enhanced GH release, and shiftmetabolism toward the accumulation of lean body mass[8].
Об авторе
Вышеуказанная литература была исследована, отредактировано и организовано доктором. Логан, доктор медицинских наук. Доктор. Logarholds a doctorate degree from Case Western Reserve University School of Medicine anca B.S.in molecular biology.
Научный журналАвтор
been listed as a noteworthy Chemist, researcher by Marquis Who’sDr. Jan lzdebski hasMaster of Science from University Warsaw, Poland, 1959 and is a Who. He attained a Doctor of Philosoph,University Warsaw, Poland, 1965, along with a Doctor of Science,University Warsaw,oland, 1979.He studied how GRF 1-29 is more resistant toenzymatic degradaton and how that affects its half-life.
Доктор. Jan lzdebski iseing referenced as one of the leading scientists involved in theresearch and develpment of GRF 1-29.In no way is this doctor/scientist endorsing oradvocating the purcase, распродажа, или использование этого продукта по любой причине. Нет никаких аффилированных отношений, imped or otherwise, между PEPTIDE GURUS и этим врачом. Thepurpose of citing thedoctor is to acknowledge, распознавать, and credit the exhaustivepment efforts conducted by the scientists studying this peptide. Dr.research and devel Jan lzdebski is listein [9]по указанным цитатам.
Ресурсы
1.Т. lto et al., “Gl side-effects of a possible therapeutic GRF analogue in monkeysare likely due to VlP receptor agonist activity,” Пептиды, том. 22,no.7, пп. 1139-1151.июль. 2001.[ПабМед]
2.M.Waelbroeck,P.Robberecht, D.H. Coy, J.-C.Camus, п. Д. Neef, and J.Christophe, “Interaction of Growth Hormone-Releasing Factor (ГРФ) и 14 GRFAnalogs with Vasoactive Intestinal Peptide (VP) Receptors of Rat Pancreas.Discovery of(N-Ac-Tyr1,D-Phe2)-ГРФ(1-29)-NH2 as a VlP Antagonist,Эндокринология,vol.116,no.6, pp.2643-2649,Jun.1985.[ПабМед]
3.A.V. Шалли,X.Zhang,R.Cai, J.M.Hare, р. Granata, И м. Bartoli, “Actionsand potential therapeutic applications ot arowth hormone-releasina hormoneagonists,Эндокринология. [ПабМед]
4.N.B.Andersen,K.Malmlöf, P.B. Johansen,Т. Т. Andreassen, г. Ørtoft, and H.Oxlund,“The qrowth hormone secretagogue ipamorelin counteracts glucocorticoid.induced decrease in bone formation of adult rats,” Гормон роста, lGF Res, Off J.Growth Horm.Res.Soc.Int.IGF Res.Soc., vol.11,no.5,pp.266-272, 0ct. 2001[ПабМед]
5.Свенссон и др., “The GH secretagogues ipamorelin and GH-releasing peptide-6increase bone mineral content in adult female rats,» Дж.. Эндокринол.. том. 165. нет. 3.pp.569-577,Jun.2000.[ПабМед]
6.М. Хеффернан и др., “The Effects of Human GH and lts Lipolytic Fragment(АОД9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andB3-AR Knock-Out Mice,”Эндокринология, том. 142,no.12, pp.5182-5189, Dec.2001.[ПабМед]
7.р. Феррер-Лоренте, С. Кэбот, Ж.-А. Фернандес-Лопес, И м. Немецкий, “Combinedeffects of oleoy-estrone and a beta3-adrenergic agonist (CL316,243) on lipidstores of diet-induced overweight male Wistar rats,Науки о жизни., том. 77, нет. 16, pp.2051-2058,Sep.2005.[ПабМед]
8.Ф. М. Из, J.Sun, л. Шарма, р. Обратите на это внимание, Вт. Дж. Цзян, и Р. Джанелло, “Metabolicstudies of a synthetic lipolytic domain (АОД9604) гормона роста человека,Horm.Res., vol.53, №6, pp.274-278,2000.[ПабМед]
9.Izdebski, Дж., и другие. “Potent Trypsin-Resistant HGH-RH Analogues.” Journa/ of PEPTIDE GURUS :An Oficial Publication of the European Peptide Society, 200410.1002/PSC.563.[Semantics Scholar]
ВСЕ СТАТЬИ И ИНФОРМАЦИЯ О ПРОДУКТЕ, ПРЕДОСТАВЛЕННЫЕ НА ЭТОМ ВЕБ-САЙТЕ, ПРЕДНАЗНАЧЕНЫ ТОЛЬКО ДЛЯ ИНФОРМАЦИОННЫХ И ОБРАЗОВАТЕЛЬНЫХ ЦЕЛЕЙ..
Продукты, предлагаемые на этом сайте, предназначены только для исследований in vitro.. исследования in vitro(латинский: в стекле) выполняются вне тела. Эти продукты не являются лекарствами и не были одобрены FDA для предотвращения, лечить или лечить любое заболевание, недуг или болезнь. Телесное введение любого вида в организм человека или животного строго запрещено законом..
